stonks4u
Sign up free
HROW logo

HROW Harrow Health, Inc.

NASDAQ Global Market · Drug Manufacturers - Specialty & Generic · Healthcare

$40.03
+1.16 (+2.98%)

Harrow Health, Inc. operates as a healthcare enterprise with a specialized focus on ophthalmic solutions. The company's portfolio includes ImprimisRx, a business dedicated to ophthalmology outsourcing and pharmaceutical compounding, as well as DEXYCU, a product utilized for managing post-operative inflammation. Beyond its direct offerings, Harrow Health maintains equity investments in several phar…

Market Cap: $1.49Bwww.harrow.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

160
3073117160
Aug 10Aug 11

Quote

Day Range
$38.87 – $41.23
52-Week Range
$28.54 – $54.85
Volume
$512.1K
Market Cap
$1.49B
50-Day Avg
$40.59
200-Day Avg
$41.12
Prev Close
$38.87
Open
$39.20

Valuation & Ratios

P/E Ratio
-350.00
EPS
$-0.14
P/B Ratio
34.35
P/S Ratio
6.61
Debt/Equity
4.80
Current Ratio
2.20
Dividend Yield
+0.0%
Gross Margin
+75.1%

Returns & Efficiency

Return on Equity
-9.8%
Return on Assets
-1.3%
FCF Yield
+2.4%
EV/EBITDA
47.88

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$272.30M$-5.14M$-0.14
2024$199.61M$-17.48M$-0.49
2023$130.19M$-24.41M$-0.75
2022$88.59M$-14.09M$-0.51
2021$72.48M$-18.01M$-0.69

Social Signal Score

51
5d
51
3 mentions
—
30d
51
3 mentions
—
60d
51
3 mentions
—
90d
51
3 mentions
—
news: 3

Earnings

Mon, Nov 9(in 3 months)

Consensus estimate $0.23 per share

2of 7 quarters beat consensus

Typical surprise -35.0% (median, so one quarter with a near-zero estimate can't distort it)

  • Mon, Aug 10$-0.46 vs $-0.18miss
  • Mon, May 11$-0.74 vs $-0.43miss
  • Mon, Mar 2$0.26 vs $0.40miss
  • Mon, Nov 10$0.33 vs $0.22beat
  • Mon, Aug 11$0.24 vs $0.31miss
  • Thu, May 8$-0.38 vs $0.02miss

Estimates and results for HROW via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

HROWhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (3)

  • Newsseekingalpha.com·4d ago·Positive

    Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript Harrow, Inc. (HROW) Q2 2026 Earnings Call Transcript

    View source ↗
  • Newsmarketbeat.com·4d ago·Neutral

    Harrow Q2 Earnings Call Highlights Harrow NASDAQ: HROW reported second-quarter revenue of $70.7 million, up 11% from a year earlier and about 60% sequentially, as the ophthalmic pharmaceutical company said it entered the second half of 2026 with stronger demand across several products, improved pricing and expanded commercial infrastructure.

    View source ↗
  • Newszacks.com·4d ago·Negative

    Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates Harrow (HROW) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.24 per share a year ago.

    View source ↗